Lifesaver for patients suffering from critical COVID-19 with respiratory failur
$NRX Pharmaceuticals(NRXP.US$
This medicine could bring an end to the current Covid19 situation with such impressive result. A nine-fold advantage was also seen in the cumulative probability of recovery from respiratory failure.
Drug Aviptadil
$NRX Pharmaceuticals(NRXP.US$
was shown to improve survival better than the standard of care treatment in an open-label trial in high comorbidity patients suffering from critical COVID-19 with respiratory failure.The study showed 60-day survival in 81% of those treated with aviptadil, compared with 21% among those who were given standard of care treatment. A similar nine-fold advantage was also seen in the cumulative probability of recovery from respiratory failure.
https://www.prnewswire.com/news-releases/journal-of-infectious-diseases-and-treatment-publishes-positive-trial-data-of-aviptadil-in-high-comorbidity-patients-suffering-from-critical-covid-19-with-respiratory-failure-301400092.html
This medicine could bring an end to the current Covid19 situation with such impressive result. A nine-fold advantage was also seen in the cumulative probability of recovery from respiratory failure.
Drug Aviptadil
$NRX Pharmaceuticals(NRXP.US$
was shown to improve survival better than the standard of care treatment in an open-label trial in high comorbidity patients suffering from critical COVID-19 with respiratory failure.The study showed 60-day survival in 81% of those treated with aviptadil, compared with 21% among those who were given standard of care treatment. A similar nine-fold advantage was also seen in the cumulative probability of recovery from respiratory failure.
https://www.prnewswire.com/news-releases/journal-of-infectious-diseases-and-treatment-publishes-positive-trial-data-of-aviptadil-in-high-comorbidity-patients-suffering-from-critical-covid-19-with-respiratory-failure-301400092.html
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
